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E-mail: pmenendez@carrerasresearch.orgHuman pluripotent stem cells (hPSCs) and mesenchymal stro-
mal/stem cells (hMSCs) are clinically relevant sources for
cellular therapies and for modeling human development and
disease. Many stem cell-based applications rely on the ability
to activate several endogenous genes simultaneously to modify
cell fate. However, genetic intervention of these cells remains
challenging. Several catalytically dead Cas9 (dCas9) proteins
fused to distinct activation domains can modulate gene expres-
sion when directed to their regulatory regions by a specific sin-
gle-guide RNA (sgRNA). In this study, we have compared the
ability of the first-generation dCas9-VP64 activator and the
second-generation systems, dCas9-SAM and dCas9-SunTag,
to induce gene expression in hPSCs and hMSCs. Several stem
cell lines were tested for single andmultiplexed gene activation.
When the activation of several genes was compared, all three
systems induced specific and potent gene expression in both
single and multiplexed settings, but the dCas9-SAM and
dCas9-SunTag systems resulted in the highest and most consis-
tent level of gene expression. Simultaneous targeting of the
same gene with multiple sgRNAs did not result in additive
levels of gene expression in hPSCs nor hMSCs.We demonstrate
the robustness and specificity of second-generation dCas9 acti-
vators as tools to simultaneously activate several endogenous
genes in clinically relevant human stem cells.
INTRODUCTION
Human pluripotent stem cells (hPSCs), including both human em-
bryonic stem cells (hESCs) and human induced pluripotent stem cells
(hiPSCs), have the unique ability to self-renew indefinitely and to
differentiate, potentially, into all cell types of the human body.1,2
They provide an unprecedented system to interrogate early human
development and to provide a potential clinically relevant cell source
for regenerative medicine.3,4 Moreover, hiPSCs offer a unique plat-
form for the in vitro generation of patient-specific differentiated cells
for personalized therapies, disease modeling, and drug screening.3,4196 Molecular Therapy: Nucleic Acids Vol. 20 June 2020 ª 2020 The A
This is an open access article under the CC BY-NC-ND license (httpSimilarly, mesenchymal stem cells (MSCs) are self-renewing multipo-
tent cells present in a wide range of tissues that are capable of differ-
entiating into various tissues of mesodermal origin and display
unique immunosuppressive properties.5 MSCs represent one of the
most promising adult stem cells being used worldwide in a wide array
of clinical applications involving autoimmunity, hematology-
oncology, traumatology, and cardiology.6–8
The success of human stem cell-based applications often relies on
methods to precisely edit the donor/patient-specific genome and/or
to regulate gene expression. Manipulation of gene expression has
generally involved the delivery of exogenous cDNA using expression
or viral vectors. However, in recent years, we have witnessed the
development of strategies to activate the expression of endogenous
gene expression using an adapted version of the clustered regularly
interspaced short palindromic repeat (CRISPR)/Cas9 system. This
system was originally developed as a powerful and versatile tool for
genome editing relying on the endonuclease (Cas9) being directed
to a specific genomic site by a single-guide RNA (sgRNA), resulting
in a precise break in the target DNA.9,10 Mutations in residues
involved in DNA catalysis have generated Cas9 proteins that lack
nuclease activity while preserving DNA binding.11,12 When fused to
effector/activation domains such as VP64, VPR, or p65 and directed
to regulatory regions of a genomic locus using sgRNAs, these nucleaseuthor(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Transgenic hPSCs Expressing dCas9 Transcriptional Activators Remain Pluripotent
(A) Schematic of the different dCas9 transcriptional activators used in this study, VP64, SAM, and SunTag. (B) Schematic of the generation of stable transgenic hPSC-VP64,
hPSC-SAM, and hPSC-SunTag lines. (C) hESC-like morphology of representative colonies from hPSC-VP64, hPSC-SAM, and hPSC-SunTag lines. (D) RT-PCR confirming
(legend continued on next page)
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modulate endogenous gene expression.11,13–15 Recently, Chavez
et al.16 compared the first-generation dCas9-VP64 activator with
various second-generation dCas9 activators, including dCas9-VPR,
dCas9-SAM, and dCas9-SunTag, in several human, mouse, and fly
cell lines and demonstrated the robustness and versatility of each sys-
tem. In this study, we set out to compare single and multiplexed gene
activation of several endogenous genes in clinically relevant hPSCs
and human MSCs (hMSCs) using first-generation dCas9-VP64 acti-
vator and the second-generation activators dCas9-SAM and dCas9-
SunTag. Our data demonstrate that all dCas9 systems can induce
specific and potent gene expression, but the second-generation sys-
tems result in the highest and most consistent level of gene expression
in these cell types. We provide guidance for laboratories wanting to
adopt dCas9 activator technology to modulate gene expression in
clinically relevant human stem cells.
RESULTS
dCas9-VP64 is a fusion between the dCas9 protein and a VP64
transactivating domain.17 dCas9-SAM represents a modified
dCas9-VP64 system using a sgRNA that incorporates two protein-
binding aptamers (MS2) capable of recruiting the transcriptional
activators p65 and HSF1 (MCP-p65-HSF1) to the targeted pro-
moter.18 The dCas9-SunTag system is a fusion between the dCas9
protein to a tail of GCN4 peptides that can recruit up to 10 copies
of scFV-VP64, which amplifies the activation signal19 (Figure 1A).
We set out to compare these three dCas9 activators in clinically rele-
vant hPSCs and hMSCs. Two different hPSC lines were used: the
hESC line H9 and a hiPSC line previously generated and character-
ized in our laboratory.20 Two distinct hMSC lines were used, one
derived from bone marrow (BM) and another from adipose tissue
(Ad). Human PSCs and MSCs were lentivirally infected with each
dCas9 system at identical multiplicity of infection (MOI) of 6 to
normalize for integration events, and transduced cells were subse-
quently selected using antibiotic resistance (dCas9-VP64 and
dCas9-SAM systems) or flow cytometry (dCas9-SunTag system)
(Figure 1B). Stable expression of either dCas9 activator system did
not alter the homeostasis and potency of either hPSCs or hMSCs
(Figures 1 and 2). Antibiotic/fluorescence-activated cell sorting
(FACS)-selected modified hPSCs and hMSCs were maintained
for >20 and >10 passages, respectively, and retained normal
morphology (Figures 1C and 2A). Each transgenic stem cell line ex-
pressed comparable levels of Cas9, and also showed appropriate
expression of the corresponding activator components (VP64,
MCP, and scFV) (Figures 1D and 2B). All transgenic hPSCs
retained the expression of pluripotency-associated transcription fac-
tors (Figure 1E) and the surface marker SSEA4 (Figure 1F), and they
formed teratomas in NSG mice comprised of tissues representing all
three germ layers (Figure 1G). Similarly, transgenic hMSCs retainedexpression of the different dCas9 system components in the different transgenic hPSC
hPSC-SAM, and hPSC-SunTag lines (n = 2). Error bars indicate SEM values. (F) Represe
in untransduced hPSCs, hPSC-VP64, hPSC-SAM, and hPSC-SunTag lines. Insets repre
formed teratomas in NSG mice. Left panels show macroscopic teratomas. Right pane
198 Molecular Therapy: Nucleic Acids Vol. 20 June 2020the typical MSC immunophenotype (CD45CD73+CD90+CD105+,
Figure 2C) and differentiated equally well toward adipogenic and
osteogenic lineages (Figure 2D).
The performance of dCas-VP64, dCas-SAM, and dCas9-SunTag was
compared across several endogenous genes representative of ecto-
derm (NEUROD1), endoderm (FOXA2), and mesoderm (CXCR4)
germ layers. Three different sgRNAs were designed in the proximal
promoter (up to 250 bp upstream of the transcription start site) for
each target gene, cloned in a lentiviral vector containing a puromy-
cin-resistance cassette, and transduced into the transgenic hPSC/
hMSC lines. Gene expression was then analyzed in puromycin-
selected cells (Figure 3A). All three dCas9 activator systems demon-
strated the ability to induce robust gene expression regardless of the
locus targeted, with the second-generation systems, dCas9-SAM
and dCas9-SunTag, resulting in consistently higher levels of gene
expression in both hPSCs (Figure 3B) and hMSCs (Figure 3C). Over-
all, the dCas9-SAM and dCas9-SunTag systems activated gene
expression to comparable levels in hPSCs, but the dCas9-SunTag
tended to activate gene expression to a higher level than did dCas9-
SAM in hMSCs. These data indicate that intrinsic differences in the
cellular and (epi)genetic nature of hPSCs and hMSCs may
impact the performance of dCas9 activator systems. There was a
slight (p > 0.05) variation in gene activation between the different
sgRNAs that were used to target the same locus, but no correlation
was observed between the promoter distal-proximal region targeted
by each sgRNA and the levels of gene expression (Figures 3B and
3C). Consistent with previous reports, our data show a negative cor-
relation between the basal gene expression state and the magnitude of
activation of a given gene in both hPSCs and hMSCs (Fig-
ure 3D).16,18,21,22 To analyze the effect of recruiting multiple dCas9
activator complexes to the same locus, we co-transduced the cells
with the three different sgRNAs directed against distinct promoter re-
gions. Simultaneous targeting of the same gene with multiple sgRNAs
did not lead to additive levels of gene expression in either hPSCs or
hMSCs, suggesting that the most efficient individual sgRNA marks
a gene activation plateau for each dCas9 activator (Figures 3B and
3C). Of note, all three systems displayed comparable and relatively
few integration events in both hPSCs (between 5 and 10) and hMSCs
(between 4 and 11) (Figure 3E).
Human stem cell-based applications rely on the ability to simulta-
neously activate several endogenous geneswith the potential tomodify
cell fate. Dead Cas9-based transcriptional activators are especially
suitable to target multiple loci, requiring only the provision of one
sgRNA for each gene to be targeted. We next analyzed the feasibility
to multiplex gene activation in both hPSCs and hMSCs. The three
dCas9 activator systems performed well upon multiplexing gene
activation, although the second-generation dCas9-SAM andlines. (E) qRT-PCR expression of the indicated pluripotency genes in hPSC-VP64,
ntative FACS data confirming expression of the pluripotency surface maker SSEA-4
sent unstained cells. (G) hPSC-VP64, hPSC-SAM, and hPSC-SunTag cells similarly
ls show cellular structures representing the three germ layers.
(legend on next page)
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least in two out of the three genes targeted (Figures 4A and 4B).
We next analyzed the top in silico-predicted off-targets of FOXA2
sgRNA (MEXA3, FUT11, and BTBD17), NEUROD1 sgRNA
(CCDC88C, CLSTN1, and DUSP27), and CXCR4 sgRNA (TUSC5,
CHRFAM7A, and ADRA2B) and found them all consistently unal-
tered, demonstrating the high specificity of all dCas9 activators in
both hPSCs (Figure 4C) and hMSCs (Figure 4D). Taken together,
our study demonstrates the robustness and specificity of dCas9 activa-
tors as a means to simultaneously activate multiple transcription
factors in clinically relevant human stem cells.
DISCUSSION
Human PSCs and MSCs are relevant cell sources that hold great
promise in both basic and clinical research.4 These applications
largely rely on robust methods to precisely control gene expression
and to simultaneously activate multiple endogenous genes with the
potential to modify cell fate and/or cell function. Unfortunately,
long-term in vitro maintenance of stemness and precise genetic
manipulation using exogenous overexpression systems has long re-
mained daunting tasks. Recently, the CRISPR/Cas9 system has arisen
as a unique, powerful, and versatile tool for genome editing in a wide
range of cell types, including stem cells. More recently, dCas9 variants
lacking nuclease activity while preserving DNA binding have been
reported.11,12 When fused to activation domains such as VP64,
VPR, or p65 they can precisely modulate endogenous gene expression
in any given locus within the genome when directed to their regula-
tory regions by a specific sgRNA, thus representing a versatile tool to
regulate locus-specific gene expression.11,13–15,23
In this study, we have compared the first-generation dCas9-VP64
activator with the second-generation systems dCas9-SAM and
dCas9-SunTag for the first time in clinically relevant human stem
cells. Of note, the stable expression of each of the three dCas9 activa-
tors is compatible with stem cell homeostasis and potency, which is a
critical prerequisite for any downstream stem cell application.
The three activator systems show the ability to induce potent gene
expression in both single and multiplexed gene activation settings.
Multiplexed gene activation in stem cells is highly desired because a
simultaneous activation of several master transcription factors is
key to modulate complex transcriptional networks that dictate stem
cell fate. Despite initial work suggesting a general decrease in gene
activation upon multiplexing,18,24 our data confirm the robustness
of these systems as tools to activate complex transcriptional multi-
plexed regulation.16 In line with previous studies, the second-genera-
tion systems dCas9-SAM and dCas9-SunTag delivered higher and
more consistent levels of gene expression than did dCas9-VP64.
Interestingly, the dCas9-SAM and dCas9-SunTag systems performedFigure 2. Transgenic hMSCs Expressing dCas9 Transcriptional Activators Rem
(A) Phase-contrast morphology of hMSC-VP64, hMSC-SAM, and hMSC-SunTag culture
of the different dCas9 system components in transgenic hMSC cultures. (C) FACS ana
hMSC-VP64, hMSC-SAM, and hMSC-SunTag cultures. (D) hMSC-VP64, hMSC-SAM, a
and adipogenic (upper panels, oil red O staining) differentiation potential.
200 Molecular Therapy: Nucleic Acids Vol. 20 June 2020at a comparable level in hPSCs whereas the dCas9-SunTag was
slightly superior in hMSCs. This indicates that intrinsic cellular and
(epi)genetic differences between hPSCs and hMSCs may impact the
performance of dCas9 activator systems. In fact, differences in chro-
matin accessibility between hESCs and hESC-derived MSCs have
been reported.25 We have also demonstrated that simultaneous tar-
geting of the same gene with multiple sgRNAs did not lead to additive
levels of gene expression in neither human PSCs norMSCs suggesting
that the most efficient individual sgRNA dictates a gene activation
plateau for each dCas9 activator. This is in contrast to that described
by Chavez et al.16 for other non-stem cell lines. This could either
reflect the different nature of the cells targeted or differences in the
DNA delivery methods or a combination both. It is also plausible
that each system depends on the recruitment of different downstream
transcriptional effectors, so the availability of these within the cells
may favor certain systems. In summary, our work reveals the robust-
ness, specificity, and versatility of all dCas9 activators in single and
multiplexed gene activation systems in clinically relevant human
stem cells and demonstrates the superior levels of gene activation
by the second-generation systems.
MATERIALS AND METHODS
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents
should be directed to, and will be fulfilled by, Pablo Menéndez
(pmenendez@carrerasresearch.org).
hPSC and hMSC Cultures
Two hPSC lines were used: the hESC line H9 obtained from WiCell
(Madison, WI, USA), and a hiPSC line previously generated in our
laboratory from B cell progenitors.20 Both hPSCs were maintained
on Matrigel (BD Biosciences, San Diego, CA, USA)-coated plates in
hESCmedium as extensively reported by our group.26–28 hESCmedia
were changed daily, and hPSC cultures were split weekly. BM- and
Ad-derived hMSC cultures were maintained in Advanced DMEM
(Thermo Fisher Scientific, Waltham, MA, USA) supplemented with
10% fetal bovine serum (Sigma, St. Louis, MO, USA), L-Glutamine,
and penicillin-streptomycin-amphotericin B (Thermo Fisher Scienti-
fic), as previously reported by our group.29 hMSC cultures were
assessed daily for changes in growth rates and morphology and split
every 8–10 days. Approval for hESC/hiPSC work was obtained from
the ISCIII-Comisión Nacional de Garantías (26/2013).
dCAS9 and sgRNA Lentivectors
All vectors used in this study were obtained from Addgene (Cam-
bridge, MA, USA), including dCAS9-VP64 (#61425), MCP-p65-
HSF1 (#61426), dCAS9-10xGCN4 (#60903), and scFv-VP64
(#60904). The final constructs used to generate hPSC/hMSCs stablyain Multipotent
s revealing normal fibroblastoid-like morphology. (B) RT-PCR confirming expression
lysis revealing bona fide MSC immunophenotype (CD45CD73+CD90+CD105+) for
nd hMSC-SunTag cultures retained osteogenic (bottom panels, alizarin red staining)
(legend on next page)
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Figure 4. Multiplexed Activation of Endogenous
Genes and Off-Target Analyses in Both hPSCs and
hMSCs
Both hPSCs (A) and hMSCs (B) were simultaneously
transduced with three sgRNAs, one for each gene. Gene
expression is shown as fold change relative to non-
transduced (NT) cells. (C and D) Analysis of the top in
silico-predicted off-targets of FOXA2 sgRNA (MEXA3,
FUT11, and BTBD17), NEUROD1 sgRNA (CCDC88C,
CLSTN1, and DUSP27), and CXCR4 sgRNA (TUSC5,
CHRFAM7A, and ADRA2B) in hPSCs (C) and hMSCs (D).
Error bars indicate SEM values. Statistical significance
was determined by a Student’s t test (two-tailed). *p <
0.05, **p < 0.01. n = 4 independent experiments.
Molecular Therapy: Nucleic Acidsexpressing the different transcriptional activators are as follows: VP64
(dCAS9-VP64), SunTag (dCAS9-10xGCN4 + scFv-VP64), and SAM
(dCAS9-VP64 + MCP-p65-HSF1) (Figure 1A). For sgRNA delivery,
both the lentiGuide-Puro (#52963) or sgRNA(MS2)_puro (#73795)
backbone was Golden Gate cloned with all the guide variants accord-
ing to the established protocol.18 NEUROD1 and CXCR4 sgRNA se-
quences were taken from Chavez et al.16 The best scored FOXA2
sgRNA sequences were defined with the CRISPRa/i sgRNA designer
tool from the Broad Institute. The individual sgRNAs targeting
FOXA2 at bp 42, NEUROD1 at bp 221, and CXCR4 at bp 162
were used in multiplexing gene activation experiments.Figure 3. Direct Comparison of the Three dCas9 Transcriptional Activators in Both hPSCs and hMSC
(A) Schematic workflow for the dCas9-mediated transcriptional activation. (B and C) Gene expression analysis by
and CXCR4 (mesoderm) in hPSCs (n = 4 independent experiments using hESC and iPSC lines) (B) and hMSCs (n
(C). Three sgRNAs were tested for each gene. The genomic localization of each gRNA relative to the transcription
pooled. Gene expression is represented as fold change relative to non-transduced (NT) cells. Error bars indicate S
Student’s t test (two-tailed). *p < 0.05, **p < 0.01. (D) Inverse correlation between basal gene expression and out
hMSCs. A Pearson’s test was used to determine the correlation index (r) and p value. (E) Analysis of integration
202 Molecular Therapy: Nucleic Acids Vol. 20 June 2020Virus Production and Transduction of
hPSCs/hMSCs
A second-generation lentiviral production sys-
tem was used to produce viral particles in
HEK293T cells. The psPAX2 packaging
plasmid, pMD2.G envelope, and the lentiviral
transfer vector were co-transfected using polye-
thyleneimine (PEI) (Polysciences, Warrington,
PA, USA) as previously detailed.30 Virus-con-
taining supernatants were harvested 48–72 h
post-transfection, concentrated by ultracentri-
fugation and titered in 293T cells. For transduc-
tion, hPSCs/hMSCs were split 48 h before
exposure to viral supernatants (MOI of 6). In-
fected cells were expanded in the presence of
blasticidin (3 mg/mL for VP64) and blasticidin
plus hygromycin (3 and 60 mg/mL for SAM).
SunTag-infected cells (transduction efficiency,
1%–13%) were FACS sorted (>95% purity) us-
ing GFP and blue fluorescence protein (BFP) re-porters, thus generating hPSCs/hMSCs stably expressing the different
transcriptional activators (Figure 1B). Puromycin (0.3 mg/mL) was
added to Cas9 activator-expressing hPSCs/hMSCs to select for guide
RNA (gRNA) integration.
Quantitative Real-Time PCR
Total RNA was extracted with a Maxwell RSC simplyRNA cells kit
(Promega, Madison, WI, USA) and subsequently incubated with
Turbo DNase (Thermo Fisher Scientific) to remove potential genomic
contamination. Reverse transcription was performed with500 ng of
RNA using SuperScript III and random hexamer primers (Thermos
qRT-PCR for FOXA2 (endoderm), NEUROD1 (ectoderm),
= 4 independent experiments with BM-MSC and Ad-MSC)
start site (TSS) is shown. sgRNAs were used individually or
EM values. All statistical significance was determined by a
put gene activation for the three genes in both hPSCs and
events by genomic qPCR in hPSCs and hMSCs.
www.moleculartherapy.orgFisher Scientific). cDNA was diluted 1:4 and 1 mL was used for each
10-mL reaction. Real-time PCR was performed with PowerUp SYBR
Green master mix (Thermo Fisher Scientific) in triplicate on a Bio-
Rad (Hercules, CA, USA) CFX384 real-time system. All primer pairs
were designed with Primer-BLAST software and validated by gel elec-
trophoresis to amplify specific single products. A standard curve with
serial dilution of cDNA was always performed to guarantee correct
amplification of primer pairs. GAPDH was used as a housekeeping
gene. Table S1 shows the sequences of all primers and gRNAs used
in this study. For the off-targets analysis, the top three in silico-pre-
dicted (gRNA design checker, IDT, Coralville, IA, USA) off-targets
for FOXA2 42 (MEXA3, FUT11, and BTBD17), NEUROD1 221
(CCDC88C, CLSTN1, and DUSP27) and CXCR4 162 (TUSC5,
CHRFAM7A, and ADRA2B) were analyzed by real-time PCR in mul-
tiplexed experiments for both hMSCs and hPSCs.
Provirus Integration Analysis
Integrated lentivirus copy number analysis was performed on
genomic DNA of transduced cells by using Lenti-X provirus quanti-
tation kit (Takara, Japan) following the manufacturer`s guidelines.
Flow Cytometry Analysis
The following antibodies (Becton Dickinson, San Jose, CA, USA)
were used in FACS experiments: SSEA-4-V450, CD73-BV510,
CD105-FITC, CD90-allophycocyanin (APC), and CD45 APC-Cy7.
For staining, 200,000 cells were resuspended in 200 mL of PBS + 2%
FBS with 1:100 antibody dilution, for 20 min at 4C. Cells were
then washed twice with PBS and acquired on a FACSCanto II flow cy-
tometer equipped with FACSDiva analysis software (Becton Dickin-
son, San Jose, CA, USA).
Adipogenic and Osteogenic In Vitro Differentiation of hMSC
Cultures
hMSC differentiation was assessed by growing hMSCs in specific dif-
ferentiation media for 2–3 weeks according to the manufacturer’s in-
structions (Lonza, Basel, Switzerland). The detailed differentiation
procedure is described elsewhere.30 Briefly, for adipogenic differenti-
ation, cells were cultured in an adipogenic MSC differentiation
BulletKit (Lonza), and differentiated cells were stained with oil red
O (Sigma). For osteogenic differentiation, cells were cultured in an
osteogenic MSC differentiation BulletKit (Lonza) and differentiated
cells were stained with alizarin red-S (Sigma).29
Teratoma Formation Assay
Undifferentiated hESC/hiPSC cultures at 80%–90% confluence were
collected through enzymatic dissociation using collagenase IV, and
2 million cells were re-suspended and injected with 250 mL of
DMEM and 50 mL of Matrigel (BD Biosciences) subcutaneously in
the back of the NSG mice.31 Tumors generally developed within
6–10 weeks. When tumors reached 1-cm diameter, mice were sacri-
ficed and the teratomas removed and fixed overnight in paraformal-
dehyde-containing solution. Teratomas were then embedded in
paraffin, sectioned, and stained for hematoxylin and eosin to assess
the presence of cells representing the three germ layers.31 Animalexperimentation protocols were approved by the Animal Care Com-
mittee of the PRBB (Parc de Recerca Biomèdica de Barcelona).
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